Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Acadia Pharmaceutica (ACAD)

Acadia Pharmaceutica (ACAD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,769,941
  • Shares Outstanding, K 144,166
  • Annual Sales, $ 223,810 K
  • Annual Income, $ -245,190 K
  • 60-Month Beta 2.87
  • Price/Sales 16.47
  • Price/Cash Flow N/A
  • Price/Book 8.81

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.46
  • Number of Estimates 6
  • High Estimate -0.40
  • Low Estimate -0.60
  • Prior Year -0.51
  • Growth Rate Est. (year over year) +9.80%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.02 +2.72%
on 06/26/19
27.75 -7.39%
on 07/10/19
-0.92 (-3.46%)
since 06/19/19
3-Month
23.19 +10.82%
on 05/02/19
27.75 -7.39%
on 07/10/19
+2.12 (+8.99%)
since 04/18/19
52-Week
12.77 +101.25%
on 08/09/18
28.67 -10.36%
on 04/05/19
+8.62 (+50.47%)
since 07/19/18

Most Recent Stories

More News
ACADIA Pharmaceuticals to Announce Second Quarter 2019 Financial Results on July 31, 2019

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system...

ACAD : 25.70 (-1.72%)
New National Event Series "Parkinson's IQ + You" Launches to Educate and Empower Parkinson's Disease Patients and Care Partners

The Michael J. Fox Foundation for Parkinson's Research (MJFF) and ACADIA Pharmaceuticals announce the launch of "Parkinson's IQ + You," a series of local events across the United States in 2019 and 2020...

ACAD : 25.70 (-1.72%)
Look for Shares of Acadia Pharmaceu to Potentially Pullback after Yesterday's 2.17% Rise

Acadia Pharmaceu (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $25.89 to a high of $25.89. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high...

ACAD : 25.70 (-1.72%)
ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2019

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central...

ACAD : 25.70 (-1.72%)
Best Relative Performance in the Biotechnology Industry Detected in Shares of Acadia Pharmaceu (ACAD , CTMX , EXAS , CLVS , EXEL )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

CTMX : 11.62 (-5.14%)
EXAS : 114.88 (-1.73%)
ACAD : 25.70 (-1.72%)
Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Tops Revenue Estimates

Acadia (ACAD) delivered earnings and revenue surprises of -9.26% and 6.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

ACAD : 25.70 (-1.72%)
Acadia: 1Q Earnings Snapshot

SAN DIEGO (AP) _ Acadia Pharmaceuticals Inc. (ACAD) on Wednesday reported a loss of $85.3 million in its first quarter.

ACAD : 25.70 (-1.72%)
ACADIA Pharmaceuticals Reports First Quarter 2019 Financial Results

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central...

ACAD : 25.70 (-1.72%)
ACADIA Pharmaceuticals Initiates Phase 3 CLARITY Program with Pimavanserin as Adjunctive Treatment for Major Depressive Disorder

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central...

ACAD : 25.70 (-1.72%)
Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for

Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ACAD : 25.70 (-1.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Soft.

See More Share

Trade ACAD with:

Business Summary

Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104...

See More

Key Turning Points

2nd Resistance Point 26.92
1st Resistance Point 26.54
Last Price 25.70
1st Support Level 25.48
2nd Support Level 24.80

See More

52-Week High 28.67
Last Price 25.70
Fibonacci 61.8% 22.60
Fibonacci 50% 20.72
Fibonacci 38.2% 18.84
52-Week Low 12.77

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar